AI Article Synopsis
Article Abstract
In addition to conventional outpatient treatment 165 psoriasis patients underwent hemosorption (100 cases) or plasmapheresis (65 cases). The efferent methods used proved beneficial in 99 (60%) of the patients that got to have normal hemograms, reduced CIC and middle molecular weight peptides levels in blood. The response depended on the disease duration irrespectively of the method of efferent treatment. The remission (1-2 years) was achieved in 79 (48%) of the patients treated who developed neither side effects no complications. Compared to controls on hospital routine therapy, a mean decrease in treatment duration made 10 +/- 4 days. Efferent outpatient treatment of psoriasis is recommended for patients with torpid course of the disease and for those who is ill not longer than 5 years.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study.
Dermatol Ther (Heidelb)
January 2025
Department of Clinical and Molecular Sciences-Dermatological Clinic, Università Politecnica Delle Marche, Ancona, Italy.
Introduction: Palmoplantar psoriasis (PPp) has a profound negative impact on patients' quality of life, and it represents a therapeutic challenge, as palms and soles are difficult to treat area. Although the efficacy profile of tildrakizumab has been well evaluated in the literature, data on its use for PPp are still limited. The objective of the study was to evaluate the efficacy and safety of tildrakizumab on moderate-to-severe plaque psoriasis with involvement of the palmoplantar area.
View Article and Find Full Text PDFA complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
Psoriasis, a chronic autoimmune and non-communicable skin disease, affects 2-3% of the global population, creating a significant financial burden on healthcare systems worldwide. Treatment approaches are categorized based on disease severity, with first-line therapy focusing on topical treatments and second-line therapy encompassing phototherapy, systemic therapy, and biological therapy. Transdermal drug delivery methods present a promising alternative by enhancing drug absorption through the skin, potentially improving therapeutic outcomes while minimizing systemic adverse effects.
View Article and Find Full Text PDFClinical aspects of psoriatic arthritis: one year in review 2024.
Clin Exp Rheumatol
January 2025
Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Italy.
Psoriatic arthritis is a very pleomorphic inflammatory disease characterised by its association with psoriasis and the development of a wide spectrum of comorbidities that can impact patients' prognosis and quality of life.In recent years, several new drugs have been developed, showing significant efficacy in alleviating symptoms and signs, while maintaining a generally favourable safety profile. Despite these advancements, the management of PsA remains potentially suboptimal.
View Article and Find Full Text PDFIL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature.
JAAD Case Rep
February 2025
Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
Cureus
December 2024
Department of Dermatology, Duke University Medical Center, Durham, USA.
Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!